Buy Mycophenolic acid (Myfortic) online
Price: 5,900 UAH
Known as original brand(s)
Myfortic
Buy Mycophenolic acid (Myfortic) online with delivery. Browse medicines that contain Mycophenolic acid, compare doses and prices.
Mycophenolic acid (MPA) is a potent, selective, non-competitive, and reversible inhibitor of inosine monophosphate dehydrogenase (IMPDH), originally marketed as enteric-coated sodium mycophenolate under the brand name Myfortic (widely recognized alongside its prodrug mycophenolate mofetil under CellCept). It is indicated in transplantation medicine to prevent acute organ rejection in patients receiving kidney, heart, or liver allografts.
The mechanism of action of mycophenolic acid involves the blockade of the de novo pathway of guanosine nucleotide synthesis, which is critical for the proliferation of T- and B-lymphocytes. Because other cell types utilize salvage pathways for purine synthesis, lymphocytes exhibit selective susceptibility to MPA. This allows for effective suppression of cellular immune responses without generalized systemic toxicity.
Clinical administration of mycophenolic acid combined with calcineurin inhibitors (tacrolimus, cyclosporine) and corticosteroids significantly reduces the incidence of acute rejection episodes and improves long-term allograft survival.
Indications
Mycophenolic acid is indicated in clinical transplantation for the following conditions:
- Kidney Transplantation: Prophylaxis of acute organ rejection in adult and pediatric patients (aged 2 years and older) receiving allogeneic renal transplants (as part of a combination immunosuppressive regimen).
- Other Solid Organs (Off-label / Standard Protocols): Prevention of rejection in heart, liver, or multi-organ transplants where alternative immunosuppressants are not tolerated.
- Autoimmune Disorders (Off-label): Management of severe lupus nephritis, refractory vasculitis, and other autoimmune conditions.
- Formulation Benefits (Myfortic): The enteric-coated formulation releases MPA in the duodenum, reducing upper gastrointestinal adverse effects compared to mycophenolate mofetil.
Dosage and administration
Mycophenolic acid dosing is individualized based on patient tolerance and clinical response:
- Recommended Renal Transplant Dosage (Myfortic): The standard dose is 720 mg (equivalent to 360 mg mycophenolic acid per tablet) administered twice daily (total daily dose 1440 mg), taken with or without food.
- Equivalency (Mycophenolate Mofetil / CellCept): Equivalent total exposure is typically achieved with 1000–1500 mg administered twice daily.
- Administration Method: Myfortic tablets must be swallowed whole without crushing, splitting, or chewing to preserve the protective enteric-coated integrity.
- Monitoring: Regular complete blood counts (monitoring for leukopenia and anemia) and assessment of renal and hepatic function are mandatory. Therapeutic drug monitoring (AUC) is performed when clinically indicated.